| Name
|
Neurotensin (8-13)
|
| Other Name
|
NT(8-13)
|
| Sequence (Single letter abbreviations)
|
RRPYIL
|
| Sequence（Three letter abbreviations）
|
{ARG}{ARG}{PRO}{TYR}{ILE}{LEU}
|
| Basic description
|
Neurotensin (8-13) is the smallest active fragment of neurotensin. Neurotensin(8-13) binds to the same sites as neurotensin. However, in the human brain, neurotensin(8-13) has a er affinity for these sites than neurotensin does. The rapid degradation of neurotensin (NT) limits its clinical use in cancer imaging and therapy. Neurotensin(8–13) pseudopeptide, NT-VIII, was developed to sidestep this problem. Some changes were introduced to the sequence of neurotensin(8–13) to stabilize the molecule against enzymatic degradation: Arg8 is now N-methylated, and Lys and Tle have replaced Arg9 and Ile12, respectively. These have stabilized the molecule against enzymatic degradation without affecting its binding properties. Moreover, the increase in stability has enhanced tumor uptake, making this derivative a promising candidate for clinical use.
|
| Solubility
|
The peptide is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weight out a smaller portion of the contents.
|
| The molecular weight
|
816.990
|
| Chemical formula
|
C38H64N12O8
|
| The purity
|
> 95%
|
| Storage conditions
|
Store the peptide at -20°C.
|
| Annotation
|
|
| Documents
|
|
| Figures
|
|
| Reference
|
Hadden MK, et al. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacology. Dec 2005; 49(8): 1149-1159.
Kokko KP, et al. In vivo behavioral effects of stable, receptor-selective neurotensin[8-13] analogues that cross the blood-brain barrier. Neuropharmacology. Mar 2005; 48(3): 417-425.
|
Neurotensin (8-13)
